Born in Iran in 1996, I began my career in medicine at Bushehr University of Medical Sciences, where I earned my medical degree (MD) in 2021. After practicing as a General Practitioner for two years, my passion for research led me to pursue a Ph.D. at Taipei Medical University in Taiwan.
Since 2017, I have been actively engaged in research, focusing on the application of computational methods to solve complex problems in oncology. My work integrates the fields of cancer biology, drug design, and molecular simulation. I utilize techniques such as molecular docking and dynamics to study drug-target interactions. More recently, my research has centered on harnessing the power of artificial intelligence to revolutionize drug discovery, with a specific aim of developing novel and effective treatments for cancer.
EDUCATION
- Ph.D. in Medicine | Taipei Medical University (TMU), Taipei, Taiwan (Present)
International Ph.D. Program, Department of Medicine.
- Doctor of Medicine (M.D.) | Bushehr University of Medical Sciences, Bushehr, Iran (2014 - 2021)
Graduated as a General Practitioner (GP).
RESEARCH, TEACHING, or OTHER INTERESTS
Cancer Research, Drug Discovery, Artificial Intelligence, Modeling and Simulation
Effects of exercise interventions on health-related quality of life in older adults with osteoporosis: a systematic review and meta-analysis Guldariya Kenzhegazova, Akmaral Baspakova, Roza Suleimenova, Afshin Zare, Nadiar Mussin, et al. Peerj, 2026 Background Osteoporosis is a prevalent skeletal disorder that substantially impairs quality of life (QoL) through reduced bone mineral density, increased fracture risk, and functional decline, particularly in older adults. Aims To evaluate the effects of exercise interventions on health-related quality of life (HRQoL) in adults aged ≥50 years with osteoporosis and to identify the most effective exercise modalities and intervention durations. Methods PubMed (MEDLINE), Web of Science, and Scopus were systematically searched to February 4, 2026, following PRISMA 2020 guidelines. Randomized controlled trials assessing exercise interventions and HRQoL outcomes in adults aged ≥ 50 years with osteoporosis were included. Risk of bias was assessed using the Cochrane tool, and certainty of evidence using GRADE. Random-effects meta-analyses were conducted using standardized mean differences (SMDs) for overall mixed-instrument analyses and mean differences (MDs) for subgroup analyses restricted to comparable instruments or domains. Results Eighteen trials involving 1,591 participants were included, with 1,448 contributing data to the meta-analyses. Exploratory pooling across heterogeneous HRQoL instruments showed no significant overall effect (SMD = −0.18, 95% CI [−0.42–0.06]; I 2 ≈ 95%). In contrast, prespecified subgroup analyses demonstrated significant improvements in HRQoL, particularly with resistance training (MD = 10.58, 95% CI [6.79–14.36]) and multicomponent exercise (MD = 5.62, 95% CI [2.65–8.58]). Short-term exercise programs (<20 weeks) produced the most consistent benefits (MD = 9.91, 95% CI [7.27–12.55]). Improvements were observed across physical and mental HRQoL domains. Certainty of evidence was moderate for resistance training and short-term interventions, and low for longer-duration and multicomponent programs. Conclusions Exercise interventions, particularly resistance training, meaningfully improve HRQoL in adults aged ≥ 50 years with osteoporosis. Shorter-duration programs appear most effective, although further high-quality trials are needed to strengthen the evidence base.
Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis Raisa A Aringazina, Afshin Zare, Seyyed Mojtaba Mousavi, Nurgul Abenova, Nadiar Maratovich Mussin, et al. World Journal of Stem Cells, 2025 BACKGROUND Diabetes mellitus (DM) is a global health concern, characterized by insulin resistance and β-cell dysfunction. Traditional treatments often fail to address underlying mechanisms, necessitating alternative therapies. Mesenchymal stem cell (MSC)-based therapies have shown promise due to their regenerative and immunomodulatory properties. However, evidence on their efficacy and safety in type 2 DM remains limited and further evaluation is needed. AIM To evaluate the safety, efficacy and therapeutic potential of MSC-based therapies in type 2 DM. METHODS This systematic review analyzed studies published between 2000 and 2025, focusing on autologous and allogeneic MSC therapies in DM. Studies were identified from various databases, including clinical and preclinical trials. Outcomes related to glycemic control, insulin requirements, β-cell function, and safety were assessed. RESULTS MSC-based therapies significantly improved glycemic control, reduced insulin requirements and enhanced β-cell function in both clinical and preclinical settings. Safety profiles were favorable, with minimal adverse effects observed, primarily transient and self-limiting. No fatal events were reported. Variability in treatment outcomes and the need for standardized protocols were challenges. CONCLUSION MSC-based therapies offer a promising alternative to conventional DM treatments, significantly improving glycemic control and safety. Further research is needed to refine protocols and confirm long-term efficacy.
Anti-lung Cancer Marine Compounds: A Review Mohammad Reza Miri, Afshin Zare, Jamileh Saberzadeh, Neda Baghban, Iraj Nabipour, et al. Therapeutic Innovation and Regulatory Science, 2022
